Effect of Dopamine Agonist Treatment on Glycemic Control in Patients with Lipodystrophy

Abstract: Lipodystrophies involve the loss of subcutaneous adipose tissue, resulting in severe metabolic issues such as insulin resistance and challenging diabetes management. This case series aims to assess bromocriptine treatment response in lipodystrophy patients, offering insights into its antidiabetic effects. This retrospective analysis focused on four female lipodystrophy patients with poor glycemic control who were undergoing bromocriptine treatment. Statistical analysis used nonparametric tests. Metabolic parameters were assessed before and 3 months post-bromocriptine treatment, revealing a modest reduction in median daily insulin dose and decreased hemoglobin A1c and fasting glucose levels. Body weight remained constant, while triglyceride levels increased. Dopamine receptor expression in pancreatic β-cells and adipocytes suggests a direct impact on glucose homeostasis. While this case series hints at bromocriptine’s positive influence on glycemic control and insulin requirements in lipodystrophy patients, larger studies are essential for establishing efficacy and safety.

Cite this article as: Yıldırım Şimşir I, Özgür S, Soyaltın UE, Çetinkalp Ş. Effect of dopamine agonist treatment on glycemic control in patients with lipodystrophy. Endocrinol Res Pract. 2024;28(3):181-183.